Skip to main content
HEALIOS K.K. logo

HEALIOS K.K. — Investor Relations & Filings

Ticker · 4593 ISIN · JP3835100003 LEI · 3538005FFIDTDLUZOE53 T Professional, scientific and technical activities
Open in API
Filings indexed 74 across all filing types
Latest filing 2023-11-14 Regulatory Filings
Country JP Japan
Listing T 4593

About HEALIOS K.K.

https://www.healios.co.jp/en/

Healios K.K. is a clinical-stage biotechnology company specializing in the research and development of regenerative medicine and cell-based therapies. The company's pipeline is focused on addressing unmet medical needs in multiple therapeutic areas. Its lead programs include an allogeneic stem cell product in late-stage clinical development for ischemic stroke and Acute Respiratory Distress Syndrome (ARDS). Healios also leverages its proprietary induced pluripotent stem cell (iPSC) platform to develop next-generation treatments. This platform includes retinal pigment epithelium (RPE) cells for age-related macular degeneration and engineered natural killer (eNK) cells designed to target solid tumors. A key area of its research is the creation of Universal Donor Cells (UDCs) to produce hypoimmunogenic therapies.

Recent filings

Filing Released Lang Actions
臨時報告書
Regulatory Filings Classification · 100% confidence The document is explicitly titled "臨時報告書" (Extraordinary Report or Timely Disclosure Report) in the header and the filing section. It is submitted to the Kanto Local Finance Bureau Director ("関東財務局長") on November 14, 2023. The reason for filing is stated under Section 1 as an event that significantly impacts the consolidated financial condition, operating results, and cash flow, citing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. This structure and purpose strongly indicate a mandatory, unscheduled disclosure of a material event, which aligns best with the general category for regulatory announcements that don't fit specific periodic reports (like 10-K or IR). Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a Japanese 'Extraordinary Report' (TIR/Rinji Hokokusho) that details a significant financial event (like recognizing a large financial revenue adjustment) outside of standard quarterly or annual cycles, especially when the document itself is short and serves as a formal notification rather than the full financial statement.
2023-11-14 Japanese
臨時報告書
Share Issue/Capital Change Classification · 100% confidence The document is a 'Rinji Hokokusho' (Extraordinary Report) filed with the Kanto Local Finance Bureau in Japan. These reports are mandatory filings under the Financial Instruments and Exchange Act when significant events occur that impact a company's financial position or business operations. Since this document does not fit into specific categories like earnings releases, annual reports, or board changes, and is a formal regulatory disclosure required by Japanese law, it is classified as a Regulatory Filing (RNS).
2023-08-14 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under Article 24-4-8 of the Financial Instruments and Exchange Act of Japan, which accompanies a Quarterly Report (Shihanki Hokokusho). While it references the quarterly report, it is a formal regulatory filing confirming the accuracy of the financial statements for the second quarter (period ending June 30, 2023). Since it is a specific regulatory filing required by Japanese law for financial reporting, and does not fit into the 'Interim/Quarterly Report' category itself (which would be the full report), it is best classified as a Regulatory Filing (RNS).
2023-08-14 Japanese
四半期報告書－第13期第2四半期(2023/04/01－2023/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Healios K.K. (株式会社ヘリオス) covering the period from April 1, 2023, to June 30, 2023. It includes detailed financial statements, management analysis (MDA), and business updates, which are characteristic of an interim/quarterly financial report. It is not a mere announcement or certification, but the full report itself. H1 2023
2023-08-14 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically accompanying a Quarterly Report (Dai-ichi shihanki hokokusho). It confirms the accuracy of the financial statements for the first quarter of the 13th fiscal period (Jan 1, 2023 to Mar 31, 2023). Since it is a regulatory filing confirming the contents of a quarterly report and does not fit into the specific categories of the report itself, it is classified as a Regulatory Filing (RNS).
2023-05-12 Japanese
四半期報告書－第13期第1四半期(2023/01/01－2023/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Healios K.K. covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial statements, management analysis (MDA), and operational updates, which are characteristic of an Interim/Quarterly Report (IR). Q1 2023
2023-05-12 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.